Experience with eribulin in patients with breast cancer and cutaneous metastases: case studies

Skin localization occurs in about 25% of women with metastatic breast cancer and represents a major therapeutic challenge. Although clinical literature on response of cutaneous metastases to chemotherapy is scarce, good response to eribulin has been reported. Herein, the clinical courses of three wo...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2018-03, Vol.14 (7s), p.37-44
Main Authors: Espinosa Aunión, Ruth, Ramírez Ruda, Carmen Aida, Rodríguez López, Carmela, Curiel García, Teresa, García Saénz, José Ángel, López López, Rafael
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents - therapeutic use
Biopsy
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Cancer therapies
Chemotherapy
Clinical trials
cutaneous metastases
Endocrine therapy
eribulin
Female
Furans - therapeutic use
Humans
Ketones - therapeutic use
Lymphatic system
Mastectomy
Medical prognosis
Metastasis
Middle Aged
Patients
Plastic surgery
Quality of life
Radiation therapy
Skin & tissue grafts
Skin Neoplasms - secondary
Treatment Outcome
Ulcers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Skin localization occurs in about 25% of women with metastatic breast cancer and represents a major therapeutic challenge. Although clinical literature on response of cutaneous metastases to chemotherapy is scarce, good response to eribulin has been reported. Herein, the clinical courses of three women with skin lesions secondary to metastatic breast cancer are described. The first patient achieved a complete clinical response in skin metastases with good tolerability to fourth-line eribulin (progression-free survival [PFS]: 8.5 months). In the second case, eribulin administered as fifth-line chemotherapy produced an objective response and PFS of 6 months with good tolerability. The third patient also received eribulin in the fifth line and had a visible skin response from the first administration (PFS: 5 months).
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2017-0360